ClinicalTrials.gg
CompletedNCT01472133Updated Feb 12, 2014

Validation of Respiration Rate Algorithms

An observational study in Respiratory Rate and Pulse Oximetry, sponsored by Guy's and St Thomas' NHS Foundation Trust. Completed at 1 site in United Kingdom. Open to participants aged 18 Months and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-02-12.

Sponsored by Guy's and St Thomas' NHS Foundation Trust · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
130
Ages
18 Months and older
Sex
All
01

Study summary

Continuous accurate unobtrusive respiratory rate monitoring may lead to improved patient outcomes, as respiratory rate is thought to be a sensitive marker of patient deterioration. Currently systems are not suitable for long term monitoring, particularly in ambulant patients as they are too restrictive. To ensure that our algorithms are suitable for use in a clinical context we need to demonstrate their performance not only in the optimal situation, healthy volunteers at rest, but also in more challenging situations such as where the person being monitored is moving and also in patients who have conditions which may affect their physiology in such a way that the accuracy of the respiration rate estimation may be affected.

No previous study has systematically tested algorithms deriving respiratory rate from either the ECG or the photoplethysmography (PPG) waveforms in a real -world setting.

The algorithms work by looking for changes in intervals between heartbeats and also changes in the sizes of the ECG and PPG waveforms, both of which may be caused by respiration. These changes tend to diminish with increasing age and also conditions which alter the chest movement and cardiac reflexes. Thus it is important to test our algorithms' accuracy in participants exhibiting these conditions. It is also important to ensure that the calculations of respiratory rate are accurate across a range of heart rates and respiratory rates. Our testing covers all these variables.

02

Conditions studied

  • Respiratory Rate
  • Pulse Oximetry

Keywords

  • Respiration Rate
  • ECG
  • Pulse oximetry
  • Photoplethysmograph
  • PPG
  • Physiology
03

In context

Lead sponsor

Guy's and St Thomas' NHS Foundation Trust is the lead sponsor of 294 studies on the registry; 79 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Months and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Healthy volunteers and hospital outpatients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Young Healthy Volunteers

    • Participant is willing and able to give informed consent for participation in the study.
    • Male or Female, aged between 18 and 40 years old.
  • Older Healthy Volunteers

    • Participant is willing and able to give informed consent for participation in the study.
    • Male or Female, aged 70 years or above.
  • Patients

    • Participant is willing and able to give informed consent for participation in the study.
    • Male or Female, aged 18-70 years old.
    • Participant has one of the following conditions:
    • Atrial fibrillation
    • A permanent pacemaker that is continuously active
    • Reduced chest wall movement

Exclusion criteria

Exclusion Criteria:

  • Young Healthy Volunteers

    • Any condition which might increase the risk of exercise testing
    • Any history of ischaemic heart disease
    • Any history of heart failure
    • Any structural heart disease (eg: valvular lesions, hypertrophic obstructive cardiomyopathy)
    • Any abnormalities on a resting ECG
    • Deep vein thrombosis diagnosed within the last 6 months or under active treatment
    • Uncontrolled hypertension (systolic blood pressure >220 mm Hg, diastolic >120 mm Hg)
    • Aortic aneurysm
    • Aortic or cardiovascular surgery within 6 months of recruitment
    • A family history of sudden cardiac death, congenital arrhythmia syndromes or cardiomyopathy
    • Autonomic dysfunction, either previously diagnosed or upon testing by the research team
    • Any condition involving the brain or spinal cord
    • Diabetes
    • Alcohol consumption > 21 units/week for women and 28 units/week for men or a history of previous alcohol dependence.
    • Acute kidney injury
    • Chronic kidney disease stage 4 or 5
    • Any condition causing hepatic dysfunction
    • Presence of a permanent pacemaker (these participants would be eligible for the pacemaker group)
    • Reduced chest wall movement (these participants would be eligible for the reduced chest movement group)
    • Any acute infection requiring antibiotic treatment within 3 months of recruitment
    • Any other surgery or illness requiring hospitalisation within 3 months of recruitment
    • Currently taking any medication with the exception of analgesics or the oral contraceptive pill.
    • Any wound or skin condition affecting the torso which may be affected by the application of adhesive ECG dots to the skin
    • Pregnancy
    • Inability to give informed consent
  • Older Healthy Volunteers

    • Any diagnosed condition primarily affecting the cardiovascular or respiratory systems
    • Symptomatic autonomic dysfunction
    • Orthostatic hypotension
    • Any condition involving the brain or spinal cord
    • Diabetes
    • Alcohol consumption > 21 units/week for women and 28 units/week for men or a history of previous alcohol dependence.
    • Acute kidney injury
    • Chronic kidney disease stage 4 or 5
    • Any condition causing hepatic dysfunction
    • Presence of a permanent pacemaker
    • Chronic Obstructive Pulmonary Disease (COPD).
    • Any muscular dystrophy
    • Kyphosis
    • Scoliosis
    • Pectus excavatum
    • Any disease involving the lungs or pleura
    • Any acute infection requiring antibiotic treatment within 3 months of recruitment
    • Any other surgery or illness requiring hospitalisation within 3 months of recruitment
    • Currently taking any medication with the exception of analgesics or the oral contraceptive pill.
    • Any wound or skin condition affecting the torso which may be affected by the application of adhesive ECG dots to the skin
    • Pregnancy
    • Inability to give informed consent
  • Patients

    • Any infection which would require isolation or barrier nursing according to the hospital's infection control policy
    • Any wound or skin condition affecting the torso which may be affected by the application of adhesive ECG dots to the skin
    • Requirement for any form of artificial ventilatory support, including oxygen therapy
    • More than one of the inclusion criteria. (ie: a patient may not have both atrial fibrillation and reduced chest wall movement and be eligible for this study)
    • Inability to give informed consent
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
130 participants (estimated)

Groups and cohorts

  • Young Healthy Volunteers

    Healthy volunteers under the age of 40

    Other: Recording of 12 lead ECG · Other: Recording of lying and standing blood pressure · Other: Recording of chest wall movement · Other: Recording of heart rate variability · Other: Recording of ECG and Pulse oximeter waveform at rest · Other: Recording of ECG and Pulse oximeter waveform during exercise

  • Older healthy volunteers

    Healthy volunteers over the age of 70

    Other: Recording of 12 lead ECG · Other: Recording of lying and standing blood pressure · Other: Recording of chest wall movement · Other: Recording of heart rate variability · Other: Recording of ECG and Pulse oximeter waveform at rest

  • Patients with atrial fibrillation

    Patients with permanent AF

    Other: Recording of 12 lead ECG · Other: Recording of lying and standing blood pressure · Other: Recording of chest wall movement · Other: Recording of heart rate variability · Other: Recording of ECG and Pulse oximeter waveform at rest

  • Patients with a pacemaker

    Patients who have an implanted pacemaker that is continually pacing

    Other: Recording of 12 lead ECG · Other: Recording of lying and standing blood pressure · Other: Recording of chest wall movement · Other: Recording of heart rate variability · Other: Recording of ECG and Pulse oximeter waveform at rest

  • Patients with restricted chest movement

    Patients whose chest expansion is less than 2.5cm

    Other: Recording of 12 lead ECG · Other: Recording of lying and standing blood pressure · Other: Recording of heart rate variability · Other: Recording of ECG and Pulse oximeter waveform at rest

Interventions

  • OtherRecording of 12 lead ECG

    Recording of 12 lead ECG

  • OtherRecording of lying and standing blood pressure

    Recording of lying and standing blood pressure

  • OtherRecording of chest wall movement

    Recording of chest wall movement

  • OtherRecording of heart rate variability

    Done during deep breathing and a valsalva manoeuvre

  • OtherRecording of ECG and Pulse oximeter waveform at rest

    For 10 mins

  • OtherRecording of ECG and Pulse oximeter waveform during exercise

    Recording of ECG and Pulse oximeter waveform during exercise

06

What researchers measure

Primary outcomes

  1. The coefficient of variation for each respiration rate algorithm

    The algorithms to be tested are: one which calculates respiration rate (RR) from ECG only, one which calculates RR from PPG only, one which calculates RR from simultaneous ECG and PPG

    Time frame: 5-6 months

Secondary outcomes

  1. The coefficient of variation for the respiration rate calculated from a second pulse oximeter

    Participants will wear two different PPG monitors to assess whether PPG monitors from different manufacturers introduce artefactual changes to the PPG morphology

    Time frame: 5-6 months

07

Study locations

1 site
  • St Thomas' Hospital
    London, SE1 7EH, United Kingdom
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 12, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01472133
Collaborators
Engineering and Physical Sciences Research Council, UK, University of Oxford
Responsible party
Richard Beale (Clinical Director, Guy's and St Thomas' NHS Foundation Trust) — Principal investigator
First posted
Nov 16, 2011
Start date
Jun 2012
Primary completion
Feb 2014
Completion
Feb 2014
Last update
Feb 12, 2014

Study contacts

Richard Beale, MBBS, FRCA
principal investigator · Guy's and St Thomas' Foundation Trust

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion